Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat

Renal Failure

Volumn 35, Issue 8, 2013, Pages 1156-1162

  Matsumoto, Mika ^a,b   Sasaki, Naoko ^a   Tsujino, Takeshi ^a   Akahori, Hirokuni ^a   Naito, Yoshiro ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KAWASAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Diabetic nephropathy; Iron restriction; Reactive oxygen species; Renal hypoxia

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DESMIN; HEMOGLOBIN; IRON; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; IRON BLOOD LEVEL; IRON RESTRICTION; KIDNEY TUBULE; LIPID DIET; MALE; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HYDRALAZINE; IRON, DIETARY; MALE; RATS; RATS, INBRED OLETF;

EID: 84881585486     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.819729     Document Type: Article

References (30)

1. Aruoma OI, Halliwell B, Laughton MJ, Quinlan GJ, Gutteridge JM. The mechanism of initiation of lipid peroxidation. Evidence against a requirement for an iron(II)-iron(III) complex. Biochem J. 1989; 258(2): 617-620.
2. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004; 291(6): 711-717.
3. Salonen JT, Tuomainen TP, Nyyssönen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ. 1998; 317(7160): 727.
4. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999; 22(12): 1978-1983.
5. Davis Jr WD, Arrowsmith WR. The treatment of hemochromatosis by massive venesection. Ann Intern Med. 1953; 39(4): 723-734.
6. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes. 1989; 38(10): 1207-1210.
7. Cooksey RC, Jones D, Gabrielsen S, et al. Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab. 2010; 298(6): 1236-1243.
8. Nankivell BJ, Chen J, Boadle RA, Harris DC. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol. 1994; 4(8): 1598-1607.
9. Harris DC, Tay C, Nankivell BJ. Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol. 1994; 21(2): 73-81.
10. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis. 1992; 20(6): 580-584.
11. Nankivell BJ, Tay YC, Boadle RA, Harris DC. Lysosomal iron accumulation in diabetic nephropathy. Ren Fail. 1994; 16(3): 367-381.
12. Facchini FS, Saylor KL. A low-iron-available, polyphenolenriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes. 2003; 52(5): 1204-1209.
13. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992; 41(11): 1422-1428.
14. Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem. 1998; 253(3): 743-750.
15. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998; 71(2): 270-277.
16. de Zeeuw D, Ramjit D, Zhang Z, et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int. 2006; 69(9): 1675-1682.
17. Burnier M, Zanchi A. Blockade of the renin-angiotensin- aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens. 2006; 24(1): 11-25.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329(20): 1456-1462.
19. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002; 106(6): 672-678.
20. Suzaki Y, Ozawa Y, Kobori H. Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci. 2006; 3(1): 40-46.
21. Zou AP, Li N, Cowley Jr AW. Production and actions of superoxide in the renal medulla. Hypertension. 2001; 37(2): 547-553.
22. Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol. 2004; 98(1): 8-12.
23. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17(1): 17-25.
24. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia. 2003; 46(8): 1153-1160.
25. Ries M, Basseau F, Tyndal B, et al. Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging. 2003; 17(1): 104-113.
26. Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int. 2008; 73(1): 34-42.
27. Yagi K, Kim S, Wanibuchi H, et al. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension. 1997; 29(3): 728-735.
28. McClain DA, Abraham D, Rogers J, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia. 2006; 49(7): 1661-1669.
29. Fernández-Real JM, Penarroja G, Castro A, García-Bragado F, Hernández-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. 2002; 51(4): 1000-1004.
30. Minamiyama Y, Takemura S, Kodai S, et al. Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab. 2010; 298(6): 1140-1149.